---
title: Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic
  melanoma patients under immune-checkpoint inhibition
date: '2024-12-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39700646/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241220170926&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment,
  yet approximately half of patients do not respond to these therapies. Identifying
  prognostic biomarkers is crucial for treatment decisions. Our retrospective study
  assessed liquid biopsies and tumor tissue analyses for two potential biomarkers:
  danger-associated molecular pattern (DAMP) S100A8/A9 and its source, neutrophils.
  In 43 metastatic unresected stage III/IV melanoma patients, elevated serum levels
  of ...'
disable_comments: true
---
Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. Our retrospective study assessed liquid biopsies and tumor tissue analyses for two potential biomarkers: danger-associated molecular pattern (DAMP) S100A8/A9 and its source, neutrophils. In 43 metastatic unresected stage III/IV melanoma patients, elevated serum levels of ...